AIM ImmunoTech Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a quarterly filing. AIM is a clinical-stage immunopharmaceutical company focused primarily on Ampligen (rintatolimod); its products have generated little revenue.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $135,000 | $163,000 |
| Operating loss | $18.838 million | $15.152 million |
| Net loss | $19.127 million | $14.400 million |
| Basic and diluted loss per share | $0.40 | $0.45 |
| Research and development expense | $7.672 million | $5.720 million |
| Cash used in operating activities | $13.965 million | $10.368 million |
- Revenue came from Ampligen cost-recovery and clinical treatment programs; no material product sales were reported. There was no European EAP revenue in 2021.
- Gross margin is not presented as a meaningful measure in the filing; revenue was substantially below production, R&D and administrative costs.
- At year-end, cash and cash equivalents were $32.093 million and marketable securities were $16.175 million, totaling $48.268 million. Current assets were $50.213 million versus current liabilities of $673,000.
- Total assets were $57.699 million and stockholders’ equity was $56.879 million. The balance sheet reported no financing obligation at year-end; remaining liabilities included operating leases of $149,000 and redeemable warrants of $35,000.
- Accumulated deficit was $361.101 million. The company reported an impairment charge of $1.779 million and a $2.701 million loss on extinguishment of the facility-related financing obligation.
Changes versus FY2020
- Net loss widened by $4.727 million. R&D expense increased $1.952 million, mainly from higher company-sponsored clinical-trial costs, while G&A was nearly unchanged at $8.672 million.
- Operating cash use increased $3.597 million. Year-end cash and cash equivalents plus marketable securities declined by approximately $6.110 million from the prior year.
- Net proceeds from share sales were $13.042 million in 2021, compared with $61.248 million in 2020. Weighted-average shares outstanding rose to 47.34 million from 31.84 million; the year-end balance sheet reported 47.99 million common shares outstanding.
Outlook, developments and risks
- Management said available funds were expected to cover anticipated operating needs and current clinical trials for approximately 24 months, while acknowledging that additional financing may be needed. The company had no material operating revenue and did not anticipate material revenue in the near future. No revenue or earnings guidance was provided.
- In October 2021, AIM submitted an IND for a planned Phase 2 pancreatic cancer trial; the FDA placed it on clinical hold in November. AIM reported in March 2022 that the hold had been released after its February response. The planned trial is expected to enroll about 90 patients; future results and timing remain uncertain.
- Ampligen remains unapproved in the United States. The FDA issued a 2013 Complete Response Letter on the ME/CFS application, citing efficacy and safety-data issues and requesting further work. Argentina approval is also not yet equivalent to commercial launch: final inspection and product-release steps remained outstanding, with delays attributed partly to the pandemic and regulatory processes.
- The company reported early or interim clinical and laboratory findings in cancer, COVID-19 and post-COVID programs; these are investigational and do not establish efficacy. The UK medicines regulator requested additional data for a planned human challenge trial, and AIM withdrew the application and terminated its hVIVO agreement.
- In March 2022, AIM agreed to sell its New Brunswick facility for $3.9 million, subject to the purchaser’s due-diligence and termination rights. Management said the sale could reduce annual cash outflow by more than $1 million. The shift away from in-house manufacturing makes contract manufacturing capacity and FDA approvals important execution risks; Alferon N Injection production and commercial sales remained on hold.
- AIM’s principal risks include clinical-trial failure or delay, regulatory setbacks, ongoing losses and funding needs, dilution from equity issuance, manufacturing and supplier constraints, competition, and uncertain commercialization and reimbursement. The BioLife contract dispute remained unresolved; the defendant counterclaimed for $96,676, which management considered unlikely to result in an unfavorable outcome.
- The audited financial statements received an unqualified opinion. Management reported effective disclosure controls and no identified material weaknesses; the auditor was not engaged to audit internal control effectiveness. The filing identifies valuation of redeemable warrants as a critical audit matter.
Investor verification priorities
- Confirm current cash, securities, operating cash burn and the assumptions behind management’s stated 24-month funding runway.
- Track enrollment, costs, regulatory milestones and clinical outcomes for the pancreatic cancer trial and other priority Ampligen programs.
- Verify completion and proceeds of the New Brunswick property sale, expected savings, and the transition to contract manufacturing.
- Check progress on Argentina’s final release requirements and whether any commercial sales have begun; confirm the status of Alferon production and approvals.
- Review subsequent equity issuance, dilution, the $100 million shelf registration, and any financing or partnership arrangements.